TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05328414

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
Study: NCT05263726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSMP through a Mobile Applications
Description: This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
Study: NCT04569760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)
Description: Oral cannabinoid oil preparation dosed in 1ml increments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
Study: NCT04888598

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT) Angiography
Description: Measurement of retinal vessel density and distribution in the macula using new generation OCT device
Study: NCT05254600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE for Nurse Leaders Program
Description: Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RISE for Nurse Leaders Program
Description: Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
Study: NCT05126134

Intervention type: DIAGNOSTIC_TEST
Intervention: KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)
Description: completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
Study: NCT05154357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Sac
Description: Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Sac
Description: Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
Study: NCT06506214

Intervention type: OTHER
Intervention: Questionnaires
Description: Responses to questionnaires:~* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Medical Adherence Self-Report Inventory (MASRI)~* Morisky Medication Adherence Scale (MMAS4)~* Visual analog scale (VAS) on the perception of disease control~* Belief on Medicine Questionnaire (BMQ)~* Care patient Feedback measure~* Hospital Anxiety and Depression Scale (HAD)~* Dermatology Life Quality Index (DLQI)
Study: NCT04827719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST-236
Description: Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
Study: NCT04642378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNCDSS based insulin regime
Description: Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine insulin treatment regime
Description: Patients of this group will receive the insulin regime recommended by professional endocrinologists.
Study: NCT06238115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin, clopidogrel
Description: aspirin 100 mg/day, clopidogrel 75 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel
Description: aspirin 100 mg/day, clopidogrel 75 mg/day
Study: NCT05965492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Day 1: 200 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 400 mg.~Day 2 and Day 3: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 4: 100 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 5: 50 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 100 mg.~Not prescribed on Days 6 and 7.
Study: NCT06318260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutrex
Description: Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
Study: NCT05076331

Intervention type: DIAGNOSTIC_TEST
Intervention: PI-2620 tracer for Tau PET scan
Description: Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
Study: NCT04952493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Iodide I 131
Description: RAI treatment may shrink the tumor

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Iodide I 131
Description: RAI treatment may shrink the tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Iodide I 131
Description: RAI treatment may shrink the tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
Study: NCT04717609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Nerve Block
Description: Preoperative Saphenous Nerve Block for partial Meniscectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
Study: NCT05788029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic pancreaticoduodenectomy
Description: laparoscopic pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open pancreaticoduodenectomy
Description: open pancreaticoduodenectomy
Study: NCT05735236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BFR Cuff
Description: The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
Study: NCT05412381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasma (PRP) injection
Description: We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline injection
Description: Patients randomized into the control arm will receive the placebo or saline injection
Study: NCT06563596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
Study: NCT04717609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
Study: NCT06563596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
Study: NCT06646887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroporation
Description: Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroporation
Description: Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroporation
Description: Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.
Study: NCT06646458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Elderly Volunteers
Description: Take the elderly milk power 2 times every day up to 28 days
Study: NCT06646523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed bodyweight resistance training
Description: The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group (Bodyweight intervention, usual speed)
Description: The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group.
Study: NCT05731609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Intensive Personal Training
Description: Personalized power training program focused on participant goals.
Study: NCT04649242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant/BHV3000
Description: BHV3000 (rimegepant) 75 mg or 50 mg ODT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching 75 mg or 50 mg ODT placebo
Study: NCT05587491

Intervention type: DEVICE
Group type: OTHER
Intervention: Hybrid Argonplasma coagulation (HAPC)
Description: Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
Study: NCT05876377

Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech COVID-19 mRNA vaccine
Description: Pfizer-BioNTech COVID-19 Vaccine, is FDA licensed or authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
Study: NCT05949580

Intervention type: DEVICE
Intervention: MS Care Platform (icobrain ms and icompanion ms)
Description: The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant.
Study: NCT06492278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP
Description: The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.
Study: NCT04086329

Intervention type: DEVICE
Group type: OTHER
Intervention: Nanosensor
Description: The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nanosensor
Description: The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue.
Study: NCT06224283

Intervention type: PROCEDURE
Intervention: Cryoablation
Description: Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors
Study: NCT06495723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIS1
Description: The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIS1
Description: The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIS1
Description: The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIS1
Description: The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
Study: NCT06062329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony Thrombectomy System
Description: The Symphony Thrombectomy System will be used to restore blood flow to the pulmonary arteries by removing thrombus/embolus/clot using aspiration and mechanical clot engagement.
Study: NCT06227806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial Tubercle Transfer
Description: Patients will receive the TTT surgery followed by a home exercise program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Patients will receive an extensive home exercise program.
Study: NCT04712539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Given PO
Study: NCT05915117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenols of pomegranate fruit peel extract (PoPex)
Description: PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
Study: NCT06284746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirolizumab+SOX/XELOX
Description: Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX/XELOX
Description: Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Study: NCT04712539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Given PO
Study: NCT05392296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power ball
Description: experimental group getting the power ball training with conventional treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isometric hand grip strengthening exercises
Description: conventional treatment (isometric hand grip training exercises)
Study: NCT05915117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
Study: NCT05226767

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NLC-V
Description: NLC-V

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NLC-V
Description: NLC-V